April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Long-Term Evaluation of Triamcinolone Acetonide Subconjunctival Delivery for Anterior Scleritis (SITAS)
Author Affiliations & Notes
  • E. H. Sohn
    Doheny Eye Institute, Los Angeles, California
  • SITAS International Study Group
    Doheny Eye Institute, Los Angeles, California
  • Footnotes
    Commercial Relationships  E.H. Sohn, None.
  • Footnotes
    Support  NIH Core grant EY03040, RPB, Eugene de Juan Award
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5269. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. H. Sohn, SITAS International Study Group; Long-Term Evaluation of Triamcinolone Acetonide Subconjunctival Delivery for Anterior Scleritis (SITAS). Invest. Ophthalmol. Vis. Sci. 2010;51(13):5269.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : We sought to characterize the long-term efficacy and complications of subconjunctival steroid injection (SCI) for non-necrotizing, noninfectious anterior scleritis.

Methods: : 97 eyes of 80 patients with non-necrotizing and non-infectious scleritis who underwent subconjunctival injections of triamcinolone acetonide (4-40 mg depending on type of scleritis) were selected from 10 participating clinical centers in the US, Israel, Singapore, and Australia.

Results: : Average follow-up was 28 months (range 1-100 months). 87 eyes (90%) experienced resolution of signs and symptoms after one injection. 24 months after injection, 65% of eyes remained recurrence free while at 48 months, 45% were recurrence free. 12 eyes had ocular hypertension not requiring IOP-lowering therapy. 2 patients were treated with topical IOP-lowering agents alone while 3 needed surgical intervention for glaucoma. None developed scleral thinning or necrosis.

Conclusions: : SCI can effectively treat anterior scleritis with side effects limited to elevated intraocular pressure in few patients. Intraocular pressure should be closely monitored after SCI.

Keywords: sclera • inflammation • injection 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.